{
    "clinical_study": {
        "@rank": "72177", 
        "arm_group": [
            {
                "arm_group_label": "Aleglitazar Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, double-blind, placebo-controlled study will evaluate the potential of\n      aleglitazar to reduce the risk of end stage renal disease and cardiovascular mortality in\n      patients with type 2 diabetes mellitus and chronic kidney disease. Patients will be\n      randomized to receive oral daily doses of aleglitazar or matching placebo. The anticipated\n      time on study treatment is approximately 3 years."
        }, 
        "brief_title": "A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2, Kidney Disease, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients >= 18 years of age at screening\n\n          -  Diagnosis of diabetes mellitus Type 2\n\n          -  Glycosylated hemoglobin A1C (HbA1C) < 10% at screening\n\n          -  Estimated glomerular filtration rate (eGFR) >=30 and < 60 mL/min/1.73 m2\n\n          -  Urinary albumin-to-creatinine ratio (UACR) >=500 and < 5000 mg/g\n\n          -  Treatment with either angiotensin converting enzyme inhibitor or angiotensin II\n             receptor blocker for at least three months prior to screening\n\n          -  Women of child-bearing potential using a highly effective birth control method must\n             be willing to use the same method of contraception during the entire course of the\n             study\n\n        Exclusion Criteria:\n\n          -  Treatment with a PPARgamma agonist and/or PPARalpha agonist in the last 12 weeks\n             screening\n\n          -  Prior intolerance to a TDZ or fibrate\n\n          -  Previous participation in a trial with aleglitazar\n\n          -  Diagnosis or history of other types of diabetes\n\n          -  Diagnosis or history of acute metabolic diabetic complications within the past 6\n             months\n\n          -  Known primary glomerulonephritis, secondary glomerulonephritis other than diabetic\n             nephropathy or polycystic kidney disease\n\n          -  Diagnosed acute kidney injury or dialysis within 12 weeks prior to screening\n\n          -  Poorly controlled hypertension (systolic blood pressure > 160 mmHg and/or diastolic\n             blood pressure > 100 mmHg at baseline)\n\n          -  Known secondary hypertension due to renal artery stenosis, primary aldosteronism, or\n             pheochromocytoma\n\n          -  History of myocardial infarction or stroke in the past 12 weeks prior to screening\n\n          -  Symptomatic congestive heart failure NYHA class II-IV at baseline or heart failure\n             leading to hospitalization within the 12 months prior to screening\n\n          -  Diagnosed and/or treated malignancy (except for treated cases of basal cell skin\n             cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past\n             5 years\n\n          -  Inadequate liver and hematological function\n\n          -  Chronic treatment with immunosuppressive therapy\n\n          -  Women who are pregnant, intending to become pregnant during the study period,\n             currently lactating females, or women of child-bearing potential not using highly\n             effective birth control methods"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893242", 
            "org_study_id": "BC28504", 
            "secondary_id": "2013-000088-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aleglitazar Arm", 
                "description": "Aleglitazar 150 mcg oral doses, once a day for approximately 3 years", 
                "intervention_name": "Aleglitazar", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "description": "Matching placebo to aleglitazar, once a day for approximately 3 years", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "number_of_arms": "2", 
        "official_title": "A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE THE RISK OF END STAGE RENAL DISEASE AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (ALERENAL STUDY)", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to the first occurrence of either component of the composite endpoint: end stage renal disease or cardiovascular death", 
            "safety_issue": "No", 
            "time_frame": "Approximately 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893242"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to the first occurrence of any component of major adverse cardiovascular event composite (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 5 years"
            }, 
            {
                "measure": "Time to the first occurrence of any component of macrovascular composite (CV death, non fatal myocardial infarction, hospitalization for unstable angina, non fatal stroke)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 5 years"
            }, 
            {
                "measure": "Time to the first occurrence of any component of composite outcome of end-stage renal disease and all-cause mortality", 
                "safety_issue": "No", 
                "time_frame": "Approximately 5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}